Endocrinology Medical News about Dyslipidemias Drug Therapy, Combination

Your Unread Messages

See All

Hello, Mary O'connor
Manage E-mail | Logout

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

3. Rapid correction of low vitamin D status in nursing home residents

4. 2008 Exclusive Survey—Earnings: Good news for primary care income

5. Medicare pay-for-reporting effort draws fire from frustrated doctors

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia
Annals of Internal Medicine, 11/03/09

Sharma M et al. – This review of 102 studies found 2 trials that suggested lower target lipid levels were more often achieved with statin–ezetimibe combination therapy than with high–dose statin monotherapy. No firm trial evidence showed that combining a statin with another agent (bile–acid sequestrant, fibrate, ezetimibe, niacin, or omega–3 fatty acids) improved clinical outcomes (myocardial infarction, stroke, or mortality) more often than high–dose statin monotherapy.

<< Previous
Effects of teriparatide versus alendronate for treating...

Next >>
Vildagliptin in clinical practice: a review of literature

Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09 Relevance Score: 82%

Disparate Response to Metoclopramide Therapy for Gastric Feeding Intolerance in Trauma Patients With and Without Traumatic Brain Injury
Journal of Parenteral and Enteral Nutrition, 11/10/09 Relevance Score: 81%

FDA approves Twynsta a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours
Boehringer Ingelheim, 10/20/09 Relevance Score: 81%

Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence
Current Medical Research and Opinion, 10/05/09 Relevance Score: 81%

Gilead Sciences Announces Plans for Phase IV Clinical Trial Evaluating First-Line Combination Therapy Versus Monotherapy in Pulmonary Arterial Hypertension
Gilead, 11/03/09 Relevance Score: 80%